Fig. 1From: Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatmentTreatment schedule. The first visit included screening and enrollment; eligible subjects received the study patch for 3 days. Subsequently, the second visit was scheduled on the second and third days of the study, and the third visit was the end of the evaluationBack to article page